Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557120 | 1.00 | NR4A1 (0.38) | NR4A1NR4A2NR4A3SMN1; SMN2MAPT | |
| SCHEMBL556294 | 0.83 | TSHR (0.35) | NR4A1NR4A2NR4A3MAPTALDH1A1 | |
| SCHEMBL556293 | 0.83 | TSHR (0.35) | NR4A1NR4A2NR4A3MAPTALDH1A1 | |
| SCHEMBL556251 | 0.82 | NR4A1 (0.41) | NR4A1NR4A2NR4A3SMN1; SMN2MAPT | |
| SCHEMBL16069992 | 0.81 | NR4A1 (0.58) | NR4A1NR4A2NR4A3SMN1; SMN2ALDH1A1 | |
| SCHEMBL16069970 | 0.81 | NR4A1 (0.58) | NR4A1NR4A2NR4A3SMN1; SMN2ALDH1A1 | |
| SCHEMBL16069969 | 0.81 | NR4A1 (0.58) | NR4A1NR4A2NR4A3SMN1; SMN2ALDH1A1 | |
| SCHEMBL556415 | 0.80 | CA1 (0.41) | ALDH1A1 | |
| SCHEMBL556416 | 0.80 | CA1 (0.41) | ALDH1A1 | |
| SCHEMBL556709 | 0.79 | TSHR (0.38) | SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | STAT3, JAK2, STAT6 | NR4A1 1016/4885NR4A2 764/4885NR4A3 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.